Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shuanghuang Shengbai is a traditional Chinese medicine (TCM) herbal formulation primarily used to prevent and treat myelosuppression (bone marrow suppression) caused by chemotherapy in cancer patients. It is available as granules or oral liquid. The main bioactive ingredients are Astragaloside IV and saponins from Rhizoma Polygonati. Mechanistically, it promotes the proliferation of bone marrow hematopoietic stem cells and increases white blood cell counts by modulating specific microRNAs (such as upregulating miR-106b*, miR-144, miR-669k* and downregulating miR-142-3p, miR-210, and miR-223). Additionally, it inhibits the proliferation of lung cancer stem cells via other microRNA pathways. Clinical studies have shown that Shuanghuang Shengbai can reduce rates of neutropenia and other forms of myelosuppression during chemotherapy without promoting tumor growth[1][2][3][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shuanghuang shengbai.